Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02535442 · ClinicalTrials.gov registry record
Nasal Swab Study to Explore the Nasal Microbia
A clinical trial, sponsored by Kimberly-Clark Corporation.
- Completed
- Registry status
- 42
- Enrollment target
NCT02535442: Completed study, sponsored by Kimberly-Clark Corporation.
NCT02535442 is a clinical trial that has completed, run by Kimberly-Clark Corporation. The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02535442 has completed, sponsored by Kimberly-Clark Corporation.
- COMPLETED
- Registry status
- 42 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the microbial consortia and the host inflammatory factors present in the nasal passages of patients during upper respiratory symptomology and when healthy using culture and molecular analysis techniques.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2015-08 |
| Est. Completion | 2016-06 |
What the finished NCT02535442 record still lists
NCT02535442 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 42 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02535442 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02535442 about?
NCT02535442 is a clinical study titled "Nasal Swab Study to Explore the Nasal Microbia". The objective of this study is to evaluate the microbial consortia and the host inflammatory factors present in the nasal passages of patients during upper respiratory symptomology and when healthy using culture and molecular analysis techniques.
What is the current status of trial NCT02535442?
This trial is currently completed. The enrollment target is 42 participants. The study started on 2015-08. Estimated completion is 2016-06.
Who is sponsoring clinical trial NCT02535442?
This trial is sponsored by Kimberly-Clark Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia